Renowned Pharma and Biotech Development Leader, Dr. Andreas Wallnöfer,
Is Named to Optigo Biotherapeutics’ Board of Directors
as the Company Advances to IND-Enabling Studies
Vancouver, British Columbia — November 4, 2025 Optigo Biotherapeutics (“Optigo”), an ophthalmology company pioneering next-gen treatments for retinal diseases, today announced that Dr. Andreas Wallnöfer is joining its Board of Directors as the company advances its lead program to IND-enabling studies.
Dr. Wallnöfer brings more than 25 years of leadership in pharmaceutical R&D and biotech investment. Most recently, he was a Partner at Jeito Capital, where he was one of the initial lead investors in EyeBio, which was subsequently acquired by Merck in 2024 for a total deal value of US $3 billion. Before joining Jeito, he was a General Partner at BioMedPartners, where he was involved in the M&A acquisition of several companies.
Prior to turning his talents to biotech investing, Dr. Wallnöfer served on the R&D Executive Leadership Team at F. Hoffmann-La Roche AG, where he was Global Head of Clinical Research & Exploratory Development and Head of Cardiovascular & Metabolism R&D. He played a key role in the Roche/Genentech integration and in the development of Vabysmo®, one of the most successful ophthalmology launches in recent years. He has a Ph.D. in Pharmacology from the University of Basel, a clinical fellowship at the University of Leiden and an Executive MBA from IMD Lausanne.
About Optigo Biotherapeutics:
Optigo Biotherapeutics is an ophthalmology company advancing an innovative platform and portfolio of biologics to restore, preserve and enhance vision in patients with retinal diseases of high unmet need. Its lead asset, a long-acting anti-VEGF is moving toward pre-IND and GLP toxicology studies for neovascular age-related macular degeneration. Leveraging its proprietary long-acting HA-binding anchoring platform, Optigo has engineered a pipeline of assets designed to address unmet needs across multiple retinal indications.
Investors Inquiries:
Optigo Biotherapeutics
Desiree Beutelspacher
desiree@optigobio.com
+1 646 207 9959
​
Media Inquiries:
O public relations GmbH
O’Patrick Wilson
o@os-pr.com
+41 78 888 4332